Bio­Mar­in's Roc­ta­vian, once fore­cast to sell $50M to $150M last year, on­ly pulls in a frac­tion of that

In April, Bio­Marin fore­cast that its new gene ther­a­py Roc­ta­vian would bring in $50 mil­lion to $100 mil­lion in sales by the end of 2023. In­stead, it’s col­lect­ed just $3.5 mil­lion in rev­enue for a mere three pa­tients.

While the com­pa­ny had sig­nif­i­cant­ly low­ered ex­pec­ta­tions late last year, and Wall Street had low­ered them fur­ther, the pal­try sales are yet an­oth­er re­minder of just how chal­leng­ing it can be to de­liv­er com­plex, high-cost new gene ther­a­pies to the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER